Global Health Updates: EU, FDA, WHO, and Industry Movements

Recent health news highlights include the EU regulator's backing of GSK's RSV shot for adults aged 50-59, rejection of Eisai and Biogen’s Alzheimer’s drug, WHO's dispatch of polio vaccines to Gaza, EU's approval of Dutch aid for cancer isotope production, and several more pivotal healthcare industry updates.

This week's health news brings significant developments. The EU health regulator has endorsed expanded use of GSK's RSV vaccine for adults aged 50-59, awaiting formal EU Commission approval.

In a setback for Alzheimer's treatment, the EU rejected Eisai and Biogen's Leqembi, citing risks outweighing benefits. Meanwhile, the WHO is proactively sending over one million polio vaccines to Gaza following virus detection in sewage samples, stressing the urgency despite no reported cases.

Other notable events include the EU's $2.2 billion approval for Dutch medical isotope production for cancer treatment, and various legal and industrial movements within the healthcare sector.

(With inputs from agencies.)